Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Incyte Corporation
Incyte Corporation
Symphogen A/S
Memorial Sloan Kettering Cancer Center
Quadriga Biosciences, Inc.
Eli Lilly and Company
Shionogi Inc.
Incyte Corporation
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
University of Chicago
Papworth Hospital NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
Pediatric Brain Tumor Consortium